Revision 1
#64801
Store at -20C
877-616-CELL (2355)
877-678-TECH (8324)
3 Trask Lane | Danvers | Massachusetts | 01923 | USA
For Research Use Only. Not for Use in Diagnostic Procedures.
Applications:
W, IP
Reactivity:
H
Sensitivity:
Endogenous
MW (kDa):
130
Source/Isotype:
Rabbit IgG
UniProt ID:
#Q15375
Entrez-Gene Id:
2045
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Specificity/Sensitivity
Source / Purification
Background
The EphA7 receptor preferentially binds ephrin-A5 as a ligand. This ligand-receptor interaction stimulates EphA7 signaling and induces apoptotic cell death through TNFR1 and caspase-8 pathway (6,7). EphA7 plays a critical role in organ development during neural tube closure, cortical dendritic development and spine maturation as well as urine tract insertion (8-10). Secreted EphA7 has been shown to promote somatic cell reprogramming through ERK activity reduction (11). Silencing of the secreted form of EphA7 is associated with germinal center B cell lymhomas. The secreted form of EphA7 has been proposed as a soluble tumor suppresor in lymphoma (12-14).
Background References
- Wilkinson, D.G. (2000) Int Rev Cytol 196, 177-244.
- Klein, R. (2001) Curr Opin Cell Biol 13, 196-203.
- Dodelet, V.C. and Pasquale, E.B. (2000) Oncogene 19, 5614-9.
- Holder, N. and Klein, R. (1999) Development 126, 2033-44.
- Brückner, K. et al. (1997) Science 275, 1640-3.
- Lee, H. et al. (2013) Mol Cells 35, 450-5.
- Lee, H. et al. (2015) Mol Cells 38, 349-55.
- Lee, J. et al. (2013) Dev Growth Differ 55, 341-9.
- Clifford, M.A. et al. (2014) Proc Natl Acad Sci U S A 111, 4994-9.
- Weiss, A.C. et al. (2014) Development 141, 3420-30.
- Lee, J. et al. (2015) Stem Cell Reports 5, 480-9.
- Oricchio, E. and Wendel, H.G. (2012) Cell Cycle 11, 1076-80.
- Dawson, D.W. et al. (2007) Oncogene 26, 4243-52.
- Oricchio, E. et al. (2011) Cell 147, 554-64.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
W: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: Human
Trademarks and Patents
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
Revision 1